Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office:...
TOKYO and CHICAGO, Ill. – Nov. 9 2016 – Astellas Pharma Inc. (TSE: 4503, collectively with its subsidiaries “Astellas”), Donate Life America and the World Transplant Games Federation today...
Tokyo and Mainz, October 28, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a...
TOKYO and NEW YORK, Oct. 21, 2016 -- Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug...
Tokyo, October 20, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announces that it will launch the newest element in its global corporate brand campaign...
Tokyo, October 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that Astellas has terminated the discussion with the...
MONTREAL and TOKYO, 14 October 2016 – The World Anti-Doping Agency (President: Sir Craig Reedie, “WADA”) and Astellas Pharma Inc. (TSE: 4503: President and CEO: Yoshihiko Hatanaka,...
North Brunswick, N.J. and Tokyo, October, 12, 2016 – Chromocell Corporation and Astellas Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
NORTHBROOK, Ill., October 11, 2016 – Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve...
NORTHBROOK, Ill., October 11, 2016 – Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve...
Tokyo, Japan, October 7, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) and its subsidiaries jointly filed a lawsuit against Actavis Elizabeth LLC...
Tokyo, October 5, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that the "Flying Star Fund," a social contribution fund run by its employees,...
Osaka and Tokyo (Japan), September 28, 2016 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. (“Astellas”; Head Office:...
Tokyo, September 28, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it received a marketing approval of Kiklin® Granules 86.2%...
Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office:...
SAN DIEGO and TOKYO - September 19, 2016 – Vical Incorporated (Nasdaq: VICL) and Astellas Pharma Inc. (TOKYO: 4503) today announced topline results from a randomized, double-blind,...
Tokyo, September 16, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year as an index...
Tokyo, September 7, 2016 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it will donate three high-standard ambulances on First Aid Day...
HONG KONG August 19, 2016 -- Astellas Pharma Inc. (TSE: 4503, “Astellas”) and the World Transplant Games Federation (WTGF) today announced the launch of Fit for Life!, a global program to help...
Tokyo, August 9, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a new drug application to the Ministry of Health,...
Tokyo and San Francisco, July 29, 2016 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and DigiTx Partners LLC (CEO: David Kim, “DigiTx Partners”) announce...
SOUTH SAN FRANCISCO, Calif. and TOKYO, Japan, July 27, 2016 – Cytokinetics, Inc. (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that...
Tokyo, July 6, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the fifth consecutive year to be included in the...
Tokyo, June 23, 2016 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko...
BANNOCKBURN, Ill., SAN FRANCISCO, Calif., and TOKYO, Japan, May 24, 2016 – Baxalta Incorporated (NYSE: BXLT), Velocity Pharmaceutical Development, LLC (VPD) and Astellas Pharma Inc. (TSE:4503)...
Tokyo and Osaka, Japan, May 23, 2016 ---Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; Headquarters: Tokyo; TSE: 4503; "Astellas"), Daiichi Sankyo Company, Limited (President and...
Tokyo, April 27, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that its subsidiary, Astellas US LLC is co-sponsoring the C3 (Changing Cancer...
TOKYO (April 21, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Eiichi Takahashi, “Amgen Astellas”) and Astellas Pharma Inc....
Tokyo, April 18, 2016– Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, “Astellas”) would like to express our deepest sympathy to the victims of the 2016...
Tokyo, April 8, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that certain media coverage related to transfer of business of the...
Tokyo, April 1, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") today announced that it has signed a new collaborative research agreement with the...
Tokyo and Osaka, March 29, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Mitsubishi Tanabe Pharma Corporation (President and Representative Director:...
Follow us
